Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

2.

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF.

J Nucl Med. 2013 May;54(5):683-90. doi: 10.2967/jnumed.112.110890. Epub 2013 Mar 20.

3.

Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, Bordenave L, Hindié E.

Br J Haematol. 2016 Nov;175(4):652-660. doi: 10.1111/bjh.14292. Epub 2016 Aug 19.

PMID:
27539369
4.

Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.

Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-1083. doi: 10.1016/j.ijrobp.2015.04.021. Epub 2015 Apr 17.

PMID:
26031367
5.

Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.

Ganesan P, Rajendranath R, Kannan K, Radhakrishnan V, Ganesan TS, Udupa K, Lakshmipathy KM, Mahajan V, Sundersingh S, Rajaraman S, Krishnakumar R, Sagar TG.

Ann Oncol. 2015 Jun;26(6):1170-4. doi: 10.1093/annonc/mdv077. Epub 2015 Feb 20.

PMID:
25701453
6.

Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.

Okosun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C, Bower M, Cwynarski K.

AIDS. 2012 Apr 24;26(7):861-5. doi: 10.1097/QAD.0b013e32835213b1.

PMID:
22333746
7.

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.

J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28.

PMID:
25071108
8.

Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.

Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, Malhotra A, Dhawan D, Vishnubhatla S.

J Nucl Med. 2017 Apr;58(4):577-583. doi: 10.2967/jnumed.116.176511. Epub 2016 Oct 6.

PMID:
27754902
9.

FDG-PET scan in assessing lymphomas and the application of Deauville Criteria.

Awan UE, Siddiqui N, SaadUllah M, Bashir H, Farooqui ZS, Muzaffar N, Mahmmood MT.

J Pak Med Assoc. 2013 Jun;63(6):725-30.

10.

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.

Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A.

Br J Haematol. 2014 Apr;165(1):112-6. doi: 10.1111/bjh.12715. Epub 2014 Jan 6.

11.

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J Jr, Buccheri V, Meneghetti JC.

J Nucl Med. 2010 Sep;51(9):1337-43. doi: 10.2967/jnumed.109.073197. Epub 2010 Aug 18. Erratum in: J Nucl Med. 2010 Oct;51(10):1658.

12.

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD; Cancer Leukemia Group B.

Leuk Lymphoma. 2012 Nov;53(11):2143-50. doi: 10.3109/10428194.2012.676173. Epub 2012 Aug 28.

PMID:
22421007
13.

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chrétien ML, Bastie JN, Brunotte F, Casasnovas RO.

J Nucl Med. 2014 Apr;55(4):569-73. doi: 10.2967/jnumed.113.130609. Epub 2014 Feb 24.

14.

Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.

Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A.

J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16.

PMID:
26884559
15.

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12. doi: 10.1007/s00259-011-1916-8. Epub 2011 Sep 6.

PMID:
21894546
16.

An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.

Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Véra P, Tilly H, Siegel BA, Gallamini A, Casasnovas RO, Haioun C.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1312-20. doi: 10.1007/s00259-013-2435-6. Epub 2013 May 7.

PMID:
23649463
17.

High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.

Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, Ben-Bassat I, Nagler A, Avigdor A.

Acta Haematol. 2016;135(3):156-61. doi: 10.1159/000441962. Epub 2015 Nov 21.

PMID:
26588173
18.

The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A.

Am J Hematol. 2015 Jun;90(6):499-503. doi: 10.1002/ajh.23994. Epub 2015 May 10.

19.

Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.

Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, Rohren E, Garg N, Chuang H, Yehia ZA, Reddy JP, Gunther JR, Khoury JD, Suki T, Osborne EM, Oki Y, Fanale M, Dabaja BS.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):333-338. doi: 10.1016/j.ijrobp.2016.10.029. Epub 2016 Oct 22.

PMID:
28068241
20.

Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.

Gandikota N, Hartridge-Lambert S, Migliacci JC, Yahalom J, Portlock CS, Schöder H.

Cancer. 2015 Jun 15;121(12):1985-92. doi: 10.1002/cncr.29277. Epub 2015 Mar 4.

Supplemental Content

Support Center